https://www.selleckchem.com/products/VX-809.html
035) and MYO18B (P = 0.032) were both associated with less tumor size. MYO18A had no significant influence on sSCC prognosis (P = 0.686), but low expression of MYO18B was proved to be significantly associated with poor outcome of cSCC (P = 0.014). MYO18B was confirmed as an independent prognostic biomarker of cSCC (P = 0.002), indicating the favorable outcome. The expression of MYO18B was an independent prognostic biomarker of cSCC, predicting the favorable prognosis independently. Investigating the expression of MYO18B can help stratify
Like
Comment
Share
